Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
This program assesses the laboratory’s ability to detect CD30 expression in lymphomas, which has emerged as a key therapeutic target.
- One 10‑core tissue microarray slide
Shipment A: March 22
Shipment B: September 13